Recent research trends and updates on nonalcoholic fatty liver disease

Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalClinical and Molecular Hepatology
Volume25
Issue number1
DOIs
StatePublished - 1 Mar 2019

Fingerprint

Research
Pharmaceutical Preparations
Liver Diseases
Biomarkers
Non-alcoholic Fatty Liver Disease
Clinical Trials
Phenotype
Phase III Clinical Trials
Precision Medicine
Phase II Clinical Trials
Mortality
Health Services Needs and Demand
Liver
Liver Transplantation
Histology
Fibrosis
Chronic Disease
Anti-Inflammatory Agents
Obesity
Drug Therapy

Keywords

  • Clinical trial
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis

Cite this

Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG) (2019). Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 25(1), 1-11. https://doi.org/10.3350/cmh.2018.0037
Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). / Recent research trends and updates on nonalcoholic fatty liver disease. In: Clinical and Molecular Hepatology. 2019 ; Vol. 25, No. 1. pp. 1-11.
@article{1d3a5510d69848b994980da0ca7010d4,
title = "Recent research trends and updates on nonalcoholic fatty liver disease",
abstract = "Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.",
keywords = "Clinical trial, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis",
author = "{Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)} and Yoo, {Jeong Ju} and Won Kim and Won Kim and Jun, {Dae Won} and Kim, {Sang Gyune} and Yeon, {Jong Eun} and Lee, {Jin Woo} and Cho, {Yong Kyun} and Park, {Sang Hoon} and Sohn, {Joo Hyun}",
year = "2019",
month = "3",
day = "1",
doi = "10.3350/cmh.2018.0037",
language = "English",
volume = "25",
pages = "1--11",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "1",

}

Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG) 2019, 'Recent research trends and updates on nonalcoholic fatty liver disease', Clinical and Molecular Hepatology, vol. 25, no. 1, pp. 1-11. https://doi.org/10.3350/cmh.2018.0037

Recent research trends and updates on nonalcoholic fatty liver disease. / Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG).

In: Clinical and Molecular Hepatology, Vol. 25, No. 1, 01.03.2019, p. 1-11.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Recent research trends and updates on nonalcoholic fatty liver disease

AU - Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)

AU - Yoo, Jeong Ju

AU - Kim, Won

AU - Kim, Won

AU - Jun, Dae Won

AU - Kim, Sang Gyune

AU - Yeon, Jong Eun

AU - Lee, Jin Woo

AU - Cho, Yong Kyun

AU - Park, Sang Hoon

AU - Sohn, Joo Hyun

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

KW - Clinical trial

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85057764482&partnerID=8YFLogxK

U2 - 10.3350/cmh.2018.0037

DO - 10.3350/cmh.2018.0037

M3 - Review article

VL - 25

SP - 1

EP - 11

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 1

ER -

Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2019 Mar 1;25(1):1-11. https://doi.org/10.3350/cmh.2018.0037